Astellas Pharma Inc's ticker is ALPMY and the CUSIP is 04623U102. A total of 14 filers reported holding Astellas Pharma Inc in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,960,617 | -2.8% | 199,100 | -7.2% | 0.07% | -6.8% |
| Q1 2023 | $3,044,828 | -3.4% | 214,500 | +6.0% | 0.07% | +7.2% |
| Q1 2022 | $3,153,000 | +0.2% | 202,400 | +4.6% | 0.07% | +1.5% |
| Q4 2021 | $3,148,000 | +15.2% | 193,500 | +17.0% | 0.07% | +7.9% |
| Q3 2021 | $2,732,000 | -7.3% | 165,400 | -20.2% | 0.06% | -22.2% |
| Q2 2019 | $2,948,000 | -49.9% | 207,330 | -55.3% | 0.08% | -49.1% |
| Q4 2017 | $5,886,000 | -3.2% | 464,123 | -3.2% | 0.16% | -5.4% |
| Q3 2017 | $6,081,000 | -38.9% | 479,559 | -41.1% | 0.17% | -40.8% |
| Q2 2017 | $9,955,000 | -7.2% | 813,965 | -0.1% | 0.28% | -8.1% |
| Q1 2017 | $10,731,000 | -5.3% | 814,454 | -0.3% | 0.31% | -9.1% |
| Q4 2016 | $11,326,000 | -24.7% | 817,110 | -15.2% | 0.34% | -25.3% |
| Q3 2016 | $15,048,000 | – | 963,505 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RENAISSANCE GROUP LLC | 1,006,415 | $15,080,000 | 0.60% |
| Henry James International Management Inc. | 18,078 | $271,000 | 0.12% |
| QUADRANT CAPITAL GROUP LLC | 27,557 | $407,000 | 0.07% |
| SCOUT INVESTMENTS, INC. | 210,640 | $3,156,000 | 0.06% |
| Aristotle Capital Management, LLC | 442,510 | $6,631,000 | 0.04% |
| BOSTON ADVISORS LLC | 43,966 | $658,000 | 0.03% |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 2,560,399 | $38,329,000 | 0.03% |
| GLENMEDE TRUST CO NA | 306,283 | $4,588,000 | 0.02% |
| FULTON BANK, N.A. | 14,909 | $223,000 | 0.02% |
| Front Row Advisors LLC | 1,101 | $16,000 | 0.01% |